ONC Stock Overview
A precision medicine company, provides autoantibody biomarker profiling in immuno-oncology, autoimmune, and infectious diseases in Europe and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Oncimmune Holdings plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.15 |
| 52 Week High | UK£0.31 |
| 52 Week Low | UK£0.093 |
| Beta | 1.19 |
| 11 Month Change | -14.01% |
| 3 Month Change | 39.55% |
| 1 Year Change | -9.97% |
| 33 Year Change | -91.47% |
| 5 Year Change | -77.91% |
| Change since IPO | -88.42% |
Recent News & Updates
Shareholder Returns
| ONC | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -3.5% | 1.2% | 1.2% |
| 1Y | -10.0% | -13.6% | 11.6% |
Return vs Industry: ONC exceeded the UK Biotechs industry which returned -14.5% over the past year.
Return vs Market: ONC underperformed the UK Market which returned 10.6% over the past year.
Price Volatility
| ONC volatility | |
|---|---|
| ONC Average Weekly Movement | 13.8% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 9.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: ONC's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: ONC's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 38 | Martin Gouldstone | www.oncimmune.com |
Oncimmune Holdings plc, a precision medicine company, provides autoantibody biomarker profiling in immuno-oncology, autoimmune, and infectious diseases in Europe and internationally. It offers ImmunoINSIGHTS, an autoantibody profiling service that unlocks the immune system to discover and convert autoantibodies into actionable biomarkers; Sero Tag, a discovery engine which identifies relevant biomarker pool for target discovery or companion diagnostics; NavigAID, a creation of a disease-specific biomarker panel; and Autoantibody Biomarkers, a companion diagnostic biomarker. The company also provides business development and marketing services.
Oncimmune Holdings plc Fundamentals Summary
| ONC fundamental statistics | |
|---|---|
| Market cap | UK£11.49m |
| Earnings (TTM) | -UK£3.14m |
| Revenue (TTM) | UK£1.21m |
9.4x
P/S Ratio-3.6x
P/E RatioIs ONC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONC income statement (TTM) | |
|---|---|
| Revenue | UK£1.21m |
| Cost of Revenue | UK£445.00k |
| Gross Profit | UK£769.00k |
| Other Expenses | UK£3.91m |
| Earnings | -UK£3.14m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.042 |
| Gross Margin | 63.34% |
| Net Profit Margin | -258.65% |
| Debt/Equity Ratio | -404.9% |
How did ONC perform over the long term?
See historical performance and comparison